BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 23054114)

  • 21. Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome.
    Hall M; Savvatis K; Nixon K; Kyrgiou M; Hariharan K; Padwick M; Owens O; Cunnea P; Campbell J; Farthing A; Stumpfle R; Vazquez I; Watson N; Krell J; Gabra H; Rustin G; Fotopoulou C
    Ann Surg Oncol; 2019 Sep; 26(9):2943-2951. PubMed ID: 31243666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection.
    Tian WJ; Chi DS; Sehouli J; Tropé CG; Jiang R; Ayhan A; Cormio G; Xing Y; Breitbach GP; Braicu EI; Rabbitt CA; Oksefjell H; Fotopoulou C; Meerpohl HG; du Bois A; Berek JS; Zang RY; Harter P
    Ann Surg Oncol; 2012 Feb; 19(2):597-604. PubMed ID: 21732142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
    Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
    Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
    Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
    Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
    Zhao D; Wu LY; Wang XB; Li XG
    Asian Pac J Cancer Prev; 2015; 16(6):2369-73. PubMed ID: 25824766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer.
    Fehm T; Banys M; Rack B; Janni W; Marth C; Blassl C; Hartkopf A; Trope C; Kimmig R; Krawczyk N; Wallwiener D; Wimberger P; Kasimir-Bauer S
    Int J Gynecol Cancer; 2013 Jun; 23(5):839-45. PubMed ID: 23694981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic para-aortic and pelvic lymphadenectomy in early stage epithelial ovarian cancer: a prospective study.
    Ditto A; Martinelli F; Reato C; Kusamura S; Solima E; Fontanelli R; Haeusler E; Raspagliesi F
    Ann Surg Oncol; 2012 Nov; 19(12):3849-55. PubMed ID: 22707110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does omentectomy in epithelial ovarian cancer affect survival? An analysis of the Surveillance, Epidemiology, and End Results database.
    McNally L; Teng NN; Kapp DS; Karam A
    Int J Gynecol Cancer; 2015 May; 25(4):607-15. PubMed ID: 25756404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Laparoscopic versus open surgery for endometrial cancer: a minimum 3-year follow-up study.
    Ghezzi F; Cromi A; Uccella S; Siesto G; Giudici S; Serati M; Franchi M
    Ann Surg Oncol; 2010 Jan; 17(1):271-8. PubMed ID: 19826876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
    Salani R; Santillan A; Zahurak ML; Giuntoli RL; Gardner GJ; Armstrong DK; Bristow RE
    Cancer; 2007 Feb; 109(4):685-91. PubMed ID: 17219441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Up-regulation of cadherin 17 and down-regulation of homeodomain protein CDX2 correlate with tumor progression and unfavorable prognosis in epithelial ovarian cancer.
    Huang LP; Yu YH; Sheng C; Wang SH
    Int J Gynecol Cancer; 2012 Sep; 22(7):1170-6. PubMed ID: 22810971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is complete cytoreductive surgery feasible in this patient with ovarian cancer?
    Dessapt AL; Huchon C; Ngo C; Bats AS; Bensaid C; Lecuru F
    Surg Oncol; 2016 Sep; 25(3):326-31. PubMed ID: 27566040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-risk borderline ovarian tumors: analysis of clinicopathological features and prognostic impact of different follow-up strategies.
    Lorusso D; Ratti M; Ditto A; Raspagliesi F
    Oncology; 2014; 87(3):183-92. PubMed ID: 25033912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift.
    Papadia A; Bellati F; Ditto A; Bogani G; Gasparri ML; Di Donato V; Martinelli F; Lorusso D; Benedetti-Panici P; Raspagliesi F
    Ann Surg Oncol; 2015 Dec; 22(13):4204-10. PubMed ID: 25777095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hematogenous Splenic Metastases as an Independent Negative Prognosis Factor at the Moment of Primary Cytoreduction in Advanced Stage Epithelial Ovarian Cancer--A Single Center Experience.
    Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
    Anticancer Res; 2015 Oct; 35(10):5649-54. PubMed ID: 26408738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of omentectomy and random peritoneal biopsies as part of comprehensive surgical staging in apparent early-stage epithelial ovarian cancer.
    Lee JY; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    Ann Surg Oncol; 2014 Aug; 21(8):2762-6. PubMed ID: 24770785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.